Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?

Expert Review of Anticancer Therapy

Volumn 13, Issue 12, 2013, Pages 1355-1361

  Cabibbo, Giuseppe ^a   Maida, Marcello ^a   Cammà, Calogero ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Elderly; Hepatocellular carcinoma; Safety; Sorafenib; Treatment

Indexed keywords

SORAFENIB;

ADVANCED CANCER; ANOREXIA; ARTICLE; BLEEDING; CANCER PROGNOSIS; CARDIOVASCULAR DISEASE; CHEMOEMBOLIZATION; COMORBIDITY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; GERIATRIC PATIENT; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MALAISE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; RASH; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 84888233730     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.859989     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
2. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin. Liver Dis. 30(1), 3-16 (2010).
3. Cabibbo G, Craxì A. Hepatocellular cancer: optimal strategies for screening and surveillance. Dig. Dis. 27(2), 142-147 (2009).
4. Cammà C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int. 29(4), 478-80 (2009).
5. Llovet JM, Ducreux M, Lencioni R; European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56(4), 908-943 (2012).
6. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341, 2061-2067 (1999).
7. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329-338 (1999).
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 37(2), 429-442 (2003).
9. Cabibbo G, Maida M, Genco C et al. Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J. Hepatol. 4(9), 256-261 (2012).
10. Cabibbo G, Genco C, Di Marco V et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Aliment. Pharmacol. Ther. 34(2), 196-204 (2011).
11. Cabibbo G, Maida M, Genco C et al. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS ONE. 8(7), e70016 (2013).
12. Latteri F, Sandonato L, Di Marco V et al. Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. Dig. Liver Dis. 40(8), 684-689 (2008).
13. Mirici-Cappa F, Gramenzi A, Santi V et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut 59(3), 387-396 (2010).
14. Suda T, Nagashima A, Takahashi S et al. Active treatments are a rational approach for hepatocellular carcinoma in elderly patients. World J. Gastroenterol. 19(24), 3831-3840 (2013).
15. Hirokawa F, Hayashi M, Miyamoto Y et al. Surgical Outcomes and Clinical Characteristics of Elderly Patients Undergoing Curative Hepatectomy for Hepatocellular Carcinoma. J. Gastrointest. Surg. 17(11), 1929-1937 (2013).
16. Yamazaki H, Tsuji K, Nagai K et al. Efficacy and long-term outcomes of radiofrequency ablation in the elderly with hepatocellular carcinoma. Hepatol. Res. doi:10.1111/hepr.12233 (2013) (Epub ahead of print).
17. Golfieri R, Bilbao JI, Carpanese L et al.; European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators. Comparison of the survival and tolerability of radioembolization in elderly versus younger patients with unresectable hepatocellular carcinoma. J. Hepatol. 59(4), 753-761 (2013).
18. Cohen MJ, Bloom AI, Barak O et al. Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma. World J. Gastroenterol. 19(16), 2521-2528 (2013).
19. Borzio M, Fornari F, De Sio I. et al. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study Future Oncol. 9(2), 283-294 (2013).
20. Zetterman RK, Belle SH, Hoofnagle JH et al. Age and liver transplantation: a report of the Liver Transplantation Database. Transplantation 66(4), 500-506 (1998).
21. Gaynor JJ, Moon JI, Kato T et al. A cause-specific hazard rate analysis of prognostic factors among 877 adults who received primary orthotopic liver transplantation. Transplantation. 84(2), 155-165 (2007).
22. Llovet JM, Ricci S, Mazzaferro V et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
23. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10(1), 25-34 (2009).
24. Iavarone M, Cabibbo G, Piscaglia F et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54(6), 2055-2063 (2011).
25. Cammà C, Cabibbo G, Petta S et al. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology 57(3), 1046-1054 (2013).
26. Wong H, Tang YF, Yao TJ et al. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist 16(12), 1721-1728 (2011).
27. Montella L, Addeo R, Cennamo G et al. Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. Oncology 84(5), 265-272 (2013).
28. Di Costanzo GG, Tortora R, De Luca M et al. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med. Oncol. 30(1), 446 (2013).
29. Boudou-Rouquette P, Narjoz C, Golmard JL et al. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study. PLoS ONE 7(8), e42875 (2012).
30. Boudou-Rouquette P, Ropert S, Mir O et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist 17(9), 1204-1212 (2012).
31. Arrondeau J, Mir O, Boudou-Rouquette P et al. Sorafenib exposure decreases over time in patients with hepatocellular carcinoma. Invest. New Drugs 30(5), 2046-2049 (2012).
32. Cabibbo G, Rolle E, De Giorgio M et al.; HCC Working Group. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev. Anticancer Ther. 11(12), 1807-1816 (2011).
33. Cabibbo G, Palmeri L, Palmeri S, Craxì A. Should cirrhosis change our attitude towards treating non-hepatic cancer? Liver Int. 32(1), 21-27 (2012).